![]() THURSDAY, (HealthDay News) - Peresolimab, a humanized immunoglobulin G1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway, is efficacious for patients with rheumatoid arthritis, according to a study published in the May 18 issue of the New England Journal of Medicine. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report. All of our articles are chosen independent of any financial interests. HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. Any known potential conflicts of interest associated with a study or source are made clear to the reader.Įditorial and Fact-Checking Policy for more detail.Įditorial and Fact-Checking Policy HealthDay Editorial Commitment. ![]()
0 Comments
Leave a Reply. |